Pasireotida ( DrugBank: Pasireotida )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
75クッシング病2

75. クッシング病


臨床試験数 : 205 薬物数 : 176 - (DrugBank : 45) / 標的遺伝子数 : 61 - 標的パスウェイ数 : 127
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-011128-70-ES
(EUCTR)
22/09/201118/07/2011Estudio de fase III, de muchos centros, aleatorizado a dos dosis distintas de medicación sin que el médico ni el paciente sepa en cual está, para evaluar la eficacia y seguridad de pasireotida LAR (de larga duración) en pacientes con enfermedad de Cushing.Estudio de fase III, multicéntrico, aleatorizado y doble ciego, para evaluar la eficacia y seguridad de pasireotida LAR en pacientes con enfermedad de Cushing Enfermedad de Cushing
MedDRA version: 14.0;Level: LLT;Classification code 10011651;Term: Cushing's disease;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Product Name: pasireotide
Product Code: SOM230
INN or Proposed INN: Pasireotide
Product Name: pasireotide
Product Code: SOM230
INN or Proposed INN: Pasireotide
Novartis Farmacéutica, S.A.NULLNot RecruitingFemale: yes
Male: yes
162Phase 3United States;Spain;Thailand;Turkey;Russian Federation;Italy;United Kingdom;Canada;Argentina;Poland;Belgium;Brazil;Singapore;Peru;Germany;China;Japan
2EUCTR2010-024165-44-ES
(EUCTR)
22/08/201107/07/2011Estudio en el que se sabe qué fármaco toma cada paciente, llevado a cabo en varios hospitales, con Pasireotida subcutánea en pacientes con enfermedad de CushingEstudio abierto, multicéntrico, de acceso expandido de pasireotida s.c., en pacientes con enfermedad de Cushing Enfermedad de Cushing
MedDRA version: 14.0;Level: SOC;Classification code 10014698;Term: Endocrine disorders;System Organ Class: 10014698 - Endocrine disorders
MedDRA version: 14.0;Level: LLT;Classification code 10011651;Term: Cushing's disease;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Product Name: Pasireotida 300
Product Code: SOM230
INN or Proposed INN: Pasireotida
Product Name: Pasireotida 600
Product Code: SOM230B
INN or Proposed INN: Pasireotida 600
Other descriptive name: SOM230B
Product Name: Pasireotida 900
Product Code: SOM230B
INN or Proposed INN: Pasireotida 900
Other descriptive name: SOM230B
Product Name: Pasireotida 300
Product Code: SOM230
INN or Proposed INN: Pasireotida
Product Name: Pasireotida 600
Product Code: SOM230B
INN or Proposed INN: Pasireotida 600
Other descriptive name: SOM230B
Product Name: Pasireotida 900
Product Code: SOM230B
INN or Proposed INN: Pasireotida 900
Other descriptive name: SOM230B
Product Name: Pasireotida 300
Product Code: SOM230
INN or Proposed INN: Pasireotida
Product Name: Pasireotida 600
Product Code: SOM230B
INN or Proposed INN: Pasireotida 600
Other descriptive name: SOM230B
Product Name: Pasireotida 900
Product Code: SOM230B
INN or Proposed INN: Pasireotida 900
Other descriptive name: SOM230B
NOVARTIS FARMACEUTICA S.A.NULLNot RecruitingFemale: yes
Male: yes
300Phase 3Egypt;Hungary;Czech Republic;Greece;Argentina;Brazil;Thailand;Spain;Romania;Netherlands;Germany;Korea, Republic of